COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote 11/2024
06/12/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
CHEO Research Institute and Shriners Hospitals for Children Canada Collaborate to Launch First-of-its-kind Joint Pediatric Metabolic and Genetic Bone Disorders Fellowship
06/12/2024
Note to editors: A media kit , including the press release, biographies, b-roll footage, and still images, will be available upon request. OTTAWA, Ontario, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Shriners Hospitals for [...]
L'Institut de recherche du CHEO et les Hôpitaux Shriners pour enfants Canada collaborent en lançant le premier programme de Monitorat clinique conjoint sur les troubles métaboliques et génétiques de l’os chez l'enfant
06/12/2024
Note pour les rédacteurs : Une trousse pour les médias comprenant le communiqué de presse, les biographies, des séquences vidéo et images fixes sera disponible sur demande. OTTAWA, Ontario, 06 déc. 2024 (GLOBE NEWSWIRE [...]
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
06/12/2024
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the " Company ") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap [...]
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06/12/2024
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM [...]
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06/12/2024
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; [...]
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06/12/2024
Live webcast on Thursday, December 12 th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
06/12/2024
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 percent of their [...]
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
06/12/2024
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
06/12/2024
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06/12/2024
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement [...]
FluidForm Bio™ Announces Participation in the New England Venture Summit
06/12/2024
WALTHAM, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will delivery a company [...]
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
06/12/2024
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
06/12/2024
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary [...]
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
06/12/2024
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to [...]
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
06/12/2024
Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending [...]
Profound Medical Announces Proposed Public Offering of Common Shares
05/12/2024
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: [...]

Pages